NCT03542968

Brief Summary

Conventionnal cadiac magnetic resonance (CMR) is the reference to assess changes in right heart flow and pulmonary artery hemodynamics in patients with repaired Tetralogy of Fallot. 4D Flow CMR Imaging is a new imaging modality able to assess all of these parameters faster (8 min vs 30 min) and more comfortably. The aim of this study is to compare conventionnal CMR and 4D Flow CMR for the assessment of these parameters (ventricular volume, ventricular systolic function, and regurgitation of the pulmonary pathway).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 12, 2017

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

May 4, 2018

Completed
28 days until next milestone

First Posted

Study publicly available on registry

June 1, 2018

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 11, 2019

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 11, 2020

Completed
Last Updated

January 23, 2020

Status Verified

June 1, 2019

Enrollment Period

2 years

First QC Date

May 4, 2018

Last Update Submit

January 21, 2020

Conditions

Keywords

Congenital heart diseaseTetralogy of FallotImaging by 4D Flow,Magnetic resonance imagingPrevention of ventricular dysfunction

Outcome Measures

Primary Outcomes (1)

  • Comparison of the pulmonary artery regurgitation using 2D MRI and 4D Flow MRI.

    Assessment of the pulmonary artery regurgitation using 2D MRI and 4D Flow MRI : regurgitation volume (ml) and regurgitation fraction (%).

    20 min

Secondary Outcomes (1)

  • Compare the evaluation of right ventricle volumes using 2D MRI and 4D Flow MRI.

    20 min

Study Arms (2)

4D magnetic resonance imaging

EXPERIMENTAL

MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).

Procedure: magnetic resonance imaging

2D magnetic resonance imaging

SHAM COMPARATOR

MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI

Procedure: magnetic resonance imaging

Interventions

Acquisition 4D Flow magnetic resonance Imaging-8 minutes

2D magnetic resonance imaging4D magnetic resonance imaging

Eligibility Criteria

Age10 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • \- children from the age of 10 and above without any upper age limit;
  • giving their informed consent for the study;
  • with a corrected tetralogy of Fallot;
  • sent for a follow-up imaging examination with endomyocardial fibrosis screening;

You may not qualify if:

  • \- pregnant woman;
  • children \<10 years old;
  • All contraindications inherent to MRI: (claustrophobia, ferromagnetic intracorporeal foreign bodies)
  • Contraindication to contrast media injection (Gadolinium)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Marie Lannelongue

Le Plessis-Robinson, 92350, France

RECRUITING

MeSH Terms

Conditions

Heart Defects, CongenitalTetralogy of Fallot

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Marc Antoine ISORNI, Doctor

    Hôpital Marie Lannelongue

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Olaf Mercier, Professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 4, 2018

First Posted

June 1, 2018

Study Start

October 12, 2017

Primary Completion

October 11, 2019

Study Completion

April 11, 2020

Last Updated

January 23, 2020

Record last verified: 2019-06

Data Sharing

IPD Sharing
Will not share

Locations